SureTrader
Home > Boards > US Listed > Biotechs >

Inovio Pharmaceuticals, Inc. (INO)

INO RSS Feed
Add INO Price Alert      Hide Sticky   Hide Intro
Moderator: nanopatent, TomP1
Search This Board:
Last Post: 8/24/2016 7:08:13 AM - Followers: 413 - Board type: Free - Posts Today: 1

Logo: Inovio

www.inovio.com/

http://finance.yahoo.com/q/ks?s=INO

http://finance.aol.com/company/inovio-biomedical-corporation/ino/ase/institutional-ownership

F
ebruary 12, 2014 Inovio CEO Dr. Joseph Kim rings bell to open trading on NYSE- http://www.youtube.com/watch?v=95yO6hFpbUM


Float: 97.65 M

Shares Outstanding: 127.26 M


Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company?s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio?s proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio?s clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Roche,Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005. The company was founded in 1983 and is based in San Diego, California.

Currently Inovio has 12 clinical studies ( HIV, Influenza, Malaria, Hepatitis B, Hepatitis C, Breast and Lung cancer, Prostate Cancer, Head and Neck cancer, Cervical Cancer, Cervical dysplasia caused by HPV) ongoing from preclinical to phase 2.
 
Sep 10, 2013
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products. Roche will make an upfront payment of USD $10 million to Inovio. Roche will also provide preclinical R&D support and payments for near-term regulatory milestones as well as payments upon reaching certain development and commercial milestones potentially up to USD $412.5 million. Additional development milestone payments could also be made to Inovio if Roche pursues other indications with INO-5150 or INO-1800.  In addition, Inovio is entitled to receive up to double-digit tiered royalties on product sales.

VGX-3100-Phase 2 Clinical Trial initiated for the treatment Cervical dysplasia (cervical intraepithelial neoplasia or CIN) caused by HPV
Top line data release Mid 2014
May 13, 2014:  Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis
http://finance.yahoo.com/news/inovio-pharmaceuticals-acquires-early-stage-080000624.html?.tsrc=applewf

May 23, 2014: Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
http://finance.yahoo.com/news/inovio-pharmaceuticals-announces-1-4-080000629.html
1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.


Inovio’s goal is to revolutionize vaccines. With best-in-class immune responses from multiple vaccines in different disease areas, our synthetic vaccine technology is making big strides toward this important goal.



 
 



 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INO
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#13518  Sticky Note 2016 VALUE DRIVERS & MILESTONES (2nd-Half of 2016 Dr_Thorfin 08/01/16 01:50:30 PM
#4698  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 08/02/13 01:15:33 PM
#13573   GM...Just read that they injected their first recipient Cloudbreak 08/24/16 07:08:13 AM
#13572   like how they go to the slums of mikekrane 08/19/16 08:39:52 AM
#13571   Zika vaccine leaders INO & GOVX need volunteers. remind2 08/19/16 12:00:12 AM
#13570   An interesting development,.... surprised there is not some drkazmd65 08/16/16 01:42:56 PM
#13568   Dr. J. Joseph Kim, Inovio’s President & CEO, nanopatent 08/11/16 03:33:26 PM
#13567   *****INO DAY = SELL TODAY 8/9/16 TREND1 08/09/16 09:52:04 PM
#13566   IMO gonna test MA200 support at $8.1 before Dr_Thorfin 08/09/16 10:59:36 AM
#13565   Capital Resources TomP1 08/08/16 08:23:37 AM
#13564   Clinical Development TomP1 08/08/16 08:23:23 AM
#13563   thanks TREND1 08/07/16 01:43:43 PM
#13562   We are the first and so far only TomP1 08/07/16 01:42:33 PM
#13561   Do you have any info on ZIKA trials ? TREND1 08/07/16 01:39:09 PM
#13560   Nasdaq website TomP1 08/07/16 01:39:03 PM
#13559   Good enough for me. TREND1 08/07/16 01:38:13 PM
#13558   Got info from TREND1 08/07/16 01:35:32 PM
#13557   institutional ownership = 27,55% TomP1 08/07/16 01:28:41 PM
#13556   ZIKA VACCINE TREND1 08/07/16 01:21:11 PM
#13555   Short % of Float = 6% TREND1 08/07/16 01:13:36 PM
#13554   Float = 67 M TREND1 08/07/16 01:11:23 PM
#13553   Inst % Owned = 7% TREND1 08/07/16 01:10:32 PM
#13552   INO DAY TREND1 08/07/16 01:08:17 PM
#13551   Inovio Goes It Alone on Hepatitis B Immunotherapy nanopatent 08/03/16 03:37:43 PM
#13550   Roche returns second Inovio candidate, ends immunotherapy deal nanopatent 08/03/16 03:27:46 PM
#13549   And I thought Roche was a robust money nanopatent 08/03/16 02:23:55 PM
#13548   You are correct. Today's drop offers good chance docoroc2 08/03/16 12:54:16 PM
#13547   GOVX well along? You gotta be kidding right ? TomP1 08/03/16 12:25:08 PM
#13546   INO rival GOVX well along with Zika vaccine platform remind2 08/03/16 11:53:24 AM
#13545   Yes and maybe. If a Zika panic breaks out TomP1 08/03/16 11:09:19 AM
#13544   So, will INO1800 go into the same file treboriluap 08/03/16 10:52:08 AM
#13543   This is the second time Roche dumps us, TomP1 08/03/16 10:40:19 AM
#13542   I do not understand the intricacies involved here, nanopatent 08/03/16 10:04:44 AM
#13541   Coming back up slowly ClearlyStocks 08/03/16 10:02:09 AM
#13540   Its spin to say that Roche did not TomP1 08/03/16 09:50:10 AM
#13539   What IS Roche's strategy? nanopatent 08/03/16 09:26:40 AM
#13538   Over-reaction. Product not in their first-line. docoroc2 08/03/16 09:24:24 AM
#13537   While we acknowledge Roche’s strategic decision in the nanopatent 08/03/16 09:23:49 AM
#13536   Roche dumps Inovio :( TomP1 08/03/16 09:23:09 AM
#13535   Got f*cked with p/m pr ClearlyStocks 08/03/16 09:18:47 AM
#13534   Thanks ClearlyStocks 08/03/16 08:46:41 AM
#13533   Knock yourself out! headsortails2066 08/03/16 08:46:31 AM
#13532   Awesome! Mind if I share this? ClearlyStocks 08/03/16 08:44:30 AM
#13531   CNBC Ticker headsortails2066 08/03/16 08:22:58 AM
#13530   Going back up fast ClearlyStocks 08/02/16 02:56:24 PM
#13529   Now decided to take a breather. $10.36 entry ClearlyStocks 08/02/16 01:08:31 PM
#13528   Opposite way, below 10 TomP1 08/02/16 11:23:11 AM
#13525   $11 inching to 52 week high ClearlyStocks 08/02/16 08:31:47 AM
#13524   $10.89 p/m and rising ClearlyStocks 08/02/16 08:04:24 AM
#13522   Strong $10.63 close. ClearlyStocks 08/01/16 08:03:25 PM
#13520   This is going to be huge. Big Zika ClearlyStocks 08/01/16 04:34:45 PM
#13519   Inovio Pharmaceuticals (NASDAQ:INO). The company has been in Dr_Thorfin 08/01/16 02:55:36 PM
PostSubject